On Oct. 4, Brian Hill, MD, PhD, Director of the Lymphoma Program, and Mikkael Sekeres, MD, MS, Director of the Leukemia Program and Vice Chair for Clinical Research, will chair one of OncLive’s State of the Science Summits being held this year in cities across the U.S. The overall program will cover important advances in the treatment of hematologic malignancies including mantle cell lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL) and more. The Summits help community oncologists in diverse specialties stay current on the latest evidence-based treatment strategies for their patients.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Dr. Hill will discuss CLL. He is an expert in lymphoid malignancies. “This session will help participants get up-to-date on some of the newest developments in the management of hematologic malignancies,” says Dr. Hill.
Dr. Sekeres, an expert in myeloid malignancies, will discuss myelodysplastic syndromes. “This meeting will provide ‘boots on the ground’ guidance for managing these complicated cancers in an era of expanding treatment choices,” says Dr. Sekeres.
Each of the State of the Science Summits brings together academic and community-based physicians and healthcare professionals across key disciplines from medical and surgical oncology.
Other Cleveland Clinic presenters include Hetty Carraway, MD, Robert Dean, MD, and Aaron Gerds, MD, and Jason Valent, MD, staff in the Department of Hematology and Medical Oncology. The meeting will take place on Thursday, Oct. 4, from 5-9 pm at Metropolitan at the 9 hotel in Cleveland.
Visit onclive.com/meetings/soss to register.
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access
Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors
Study of 401,576 patients reveals differences in cancer burdens as well as overall survival
Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy